ICU Medical (ICUI) Q4 2025 earnings review
Divestiture Clouds Headlines, Organic Growth Slows
ICU Medical's Q4 results are noisy due to the May 2025 divestiture of the IV Solutions business, causing reported revenue to fall 14% YoY. However, the core signal is mixed: while GAAP Gross Margin expanded to 38% (up from 36% last year) due to the exit of lower-margin assets, organic growth decelerated to just 2%, down from 5% in Q3 and 10% in Q1. Adjusted EBITDA also fell YoY ($98M vs $105M). FY26 guidance suggests stabilization rather than a rapid rebound, with midpoint EBITDA growth of ~3%.
🐂 Bull Case
The exit from the IV Solutions business is actively lifting margins. GAAP Gross Margin improved 200bps YoY to 38% in Q4, validating the strategy to shed lower-margin revenue streams.
The Consumables segment remains the reliable engine, growing 6% reported and 5% organically in Q4. As the largest segment ($285M), its stability provides a floor for earnings.
🐻 Bear Case
Infusion Systems (Hardware) organic growth slowed to just 1% in Q4 (down from 8% in Q3). Without hardware placements today, the high-margin consumables tail for the future is at risk.
Despite the 'structural' margin improvements, Adjusted EBITDA actually declined YoY in Q4 ($98.2M vs $105.5M). Operating efficiencies are not yet fully offsetting the loss of divestiture scale and tariff headwinds.
⚖️ Verdict: ⚪
Neutral. The messy financials from the divestiture are stabilizing, but the underlying growth engine is sputtering (2% organic). FY26 guidance implies only low-single-digit profit growth, suggesting 2026 will be another transition year rather than a breakout.
Key Themes
Infusion Systems Deceleration
A critical slowdown occurred in the Infusion Systems segment. After posting robust 8% organic growth in Q3, growth nearly evaporated to 1% in Q4. This segment is the leading indicator for future consumables revenue; a stall here suggests either competitive pressure or a pause in hospital capital spending.
Portfolio Optimization (Vital Care)
The divestiture of IV Solutions is complete, reshaping the P&L. Vital Care revenue collapsed 58% YoY to $79.7M as expected, but this subtraction is addition for margins. GAAP Gross Margin hit 38% in Q4 vs 36% a year ago, proving the thesis that the exited business was dilutive to rates.
Tariff Exposure
While not explicitly quantified in the Q4 release text, tariffs remain a major hangover from Q3 (where they were flagged as a $25M annualized headwind). The 'Risks' section explicitly cites 'tariffs and other barriers to trade.' With EBITDA margins compressing sequentially (19.7% in Q3 to 18.2% in Q4), these costs are likely biting.
Consumables Stability
Amidst volatility elsewhere, Consumables (53% of revenue) grew 6% reported and 5% organically. This segment is the company's anchor, driven by oncology and non-IV applications.
Other KPIs
Decelerating. Down 7% YoY from $105.5M in 24Q4 and down sequentially from $106M in 25Q3. The divestiture impact and potential tariff costs outweighed gross margin improvements.
Stable. Calculated as Operating Cash Flow ($60.6M) minus CapEx ($24.6M) plus Asset Sales ($8.0M). This is an improvement over the negative FCF seen in Q2, helping stabilize the balance sheet.
Improving. Loss narrowed from $(23.8)M in the prior year period. While still unprofitable on a GAAP basis, the trend is moving in the right direction as one-time integration costs roll off.
Guidance
Stable. The midpoint ($415M) represents modest ~2.7% growth over the FY25 actual total of ~$404M. This suggests management sees 2026 as a year of consolidation rather than aggressive growth.
Stable/Accelerating. The midpoint ($8.10) implies ~4.4% growth over the FY25 derived actual of ~$7.76. This growth rate is slightly higher than EBITDA, likely driven by debt paydown reducing interest expense.
Reversing. Guidance calls for a return to GAAP profitability (midpoint $35M) compared to the GAAP Net Loss of $15.7M in Q4 alone and near breakeven for FY25 ($0.7M). This is a positive signal for earnings quality.
Key Questions
Infusion Systems Slowdown
Organic growth in Infusion Systems decelerated sharply to 1% in Q4 from 8% in Q3. Was this due to order timing, or are you seeing a structural pause in hospital capital spending?
Margin vs. Tariff Dynamics
GAAP Gross Margins improved to 38%, but Adjusted EBITDA dollars fell YoY. Can you quantify the specific drag from tariffs in Q4 and how much is embedded in the FY26 outlook?
Capital Allocation Priorities
With the IV Solutions divestiture complete and cash flow positive, will FY26 prioritize further debt reduction, or are you looking at M&A to backfill the revenue lost from the divestiture?